Navigation Links
Saladax Biomedical, Inc. Appoints Li Zhang, M.D., to Scientific Advisory Board

BETHLEHEM, Pa., Nov. 8, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Li Zhang, M.D., has been appointed to the company's scientific advisory board (SAB).

Dr. Zhang is a professor of medical oncology and deputy director of the Lung Cancer Research Centre of Sun Yat-Sen University (SYSU), chief of the department of medical oncology at the Sun-Yat Sen University Cancer Centre (SYSUCC) and associate director of the National Anti-Cancer Drug Clinical Research Centre at SYSUCC in Guangzhou, China.  Dr. Zhang's research is focused on developing molecular, prognostic and therapeutic approaches to improve the care for patients with colorectal, lung and head and neck cancers.  He is also actively involved in research focused on supportive treatment for cancer-induced anaemia (CIA) and treatment of bone metastases with bisphosphonate. 

"Dr. Zhang's extensive experience in oncology and his leadership within the Chinese medical community will be invaluable to Saladax as the company targets new indications and markets MyCare," said Edward L. Erickson, president and CEO of Saladax.  "In particular, Dr. Zhang's expertise will be critical as we continue development of MyCare for paclitaxel and docetaxel, two widely used chemotherapy drugs for breast, lung and ovarian cancers."

Dr. Zhang has been extensively involved in numerous Phase I/II studies of novel agents and international Phase III trials, either as a principle investigator and/or steering committee member.  He has also published more than 90 clinical papers in top-tier journals and is an editorial board member of the Chinese Journal of Clinical Oncology, Chinese Journal of Cancer, Asia-Pacific Journal of Clinical Oncology, Chinese Journal of Tuberculosis, Respiratory Diseases and the Chinese version of the Journal of Clinical Oncology. 

"I'm excited to be a part of Saladax's vision of providing more personalized care to patients through its MyCare platform," said Dr. Zhang.  "Saladax's technology offers patients a means of achieving optimal efficacy, while at the same time minimizing the toxicity associated with traditional chemotherapy."

Dr. Zhang earned his medical degree from the Medical School of SYSU and his board certification as a physician of medical oncology in 1986.  He continued with his post-graduate training at the CCSYSU.  He currently holds leadership positions in numerous professional societies and cooperative groups, including The Association of Rehabilitation and Palliative Care (CACA), The Cancer Chemotherapy Association and Lung Cancer Association of the Guangdong Province.  He is also a standing committee member of the Chinese Society of Clinical Oncology (CSCO).

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic cronym>assays to achieve the promise of personalized medicine through dose management and companion diagnostic products for existing and new therapeutics.  The Company's dose management technology enables physicians to optimize drug dosing to meet individual patient needs, leading to improved response and quality of life.  The Company's 15 MyCare™ dose management assays are comprised of proprietary, automated and cost-effective in vitro diagnostic tests, with a principal focus in oncology.  The first MyCare assay available is for one of the most common anticancer drugs, 5-fluorouracil (5-FU).  This assay is available in the United States from Myriad Genetics, sold by Saladax in Europe and will be distributed in Japan by FALCO biosystems.  Saladax also works with pharmaceutical companies to develop companion diagnostics to provide important clinical information to assist in developing and administering new and existing compounds.  For more information, visit, or follow us on Twitter at

Saladax Biomedical, Inc.
Edward L. Erickson
President and Chief Executive Officer

Media Contact:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
Jason Rando

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Saladax Biomedical, Inc. Announces European Commercialization Team
2. Saladax Biomedical, Inc. Announces Appointment of Gregory C. Critchfield, M.D., M.S. as Chairman of the Companys Board of Directors
3. Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
4. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
5. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
6. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Omeros Appoints David A. Mann to its Board of Directors
9. RainDance Technologies Appoints Olex Vice President, System Development
10. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
11. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):